Spectral AI, Inc. (MDAI) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Spectral AI, Inc.'s filing signal turned positive.

Spectral AI, Inc. is an AI company focused on predictive medical diagnostics, developing its DeepView System to distinguish between damaged and healthy human tissue invisible to the naked eye. The system provides a binary prediction on a wound's capacity to heal, aiming to assist healthcare professionals in making more accurate treatment decisions, initially focusing on burn indications. The company received UKCA marking for its DeepView System in the UK and anticipates FDA De Novo application submission in mid-2025. Revenue streams are planned to include a SaaS model for software licensing and maintenance, alongside the imaging device component. Significant funding has been secured from the U.S. government, primarily BARDA, to support technology development and clinical trials.

The company's primary revenue driver is research and development revenue from contracts with U.S. governmental agencies, particularly BARDA and the Defense Health Agency. Future revenue is expected from the commercialization of its DeepView System through a SaaS model and imaging device sales.